10.3390/polym8030084

Vollständiger Abstract

Worum geht es in dieser Arbeit?

<b>Background/Objectives</b>: Human immunodeficiency virus (HIV) infection is characterized by chronic systemic inflammation. Antiretroviral therapy (ART) can reduce persistent inflammation, as measured by C-reactive protein (CRP). The CRP methylation risk score (MRS CRP ) acts as proxy for plasma CRP, but longitudinal changes in this score for people with HIV (PWH) before and after initiating ART have not been described. <b>Methods</b>: We evaluated a previously published MRS CRP in the Emory Twin Study (N = 352), testing its correlation with plasma CRP and CRP-responsive biomarkers, as well as associations with cardiometabolic traits using generalized estimating equations (GEEs). We then applied MRS CRP in the HIV AIDS Drug Resistance Surveillance Study (ADReSS) cohort (N = 440) to assess longitudinal changes before and after ART, using paired <i>t</i>-tests and linear mixed-effects models. <b>Results</b>: MRS CRP showed moderate correlation with CRP (r = 0.38) and other inflammatory biomarkers (r = 0.25-0.34). MRS CRP was associated with hypertension, type 2 diabetes, coronary artery disease, and obesity, and remained independently associated with obesity (odds ratio = 1.49) after adjusting for measured CRP. Z-score-standardized MRS CRP decreased by 0.254 standard deviation units between baseline and follow-up among PWH receiving ART, confirmed by linear mixed-effects models. <b>Conclusions</b>: MRS CRP showed associations with chronic inflammation and cardiometabolic diseases. The observed decline in MRS CRP following ART initiation may reflect changes in inflammatory status among PWH. These findings highlight the potential of MRS CRP as a marker of inflammation-related changes and comorbidity risk in PWH.

Abstract: PubMed · Datensatz